Stoke Therapeutics, Inc. (STOK)

Stoke Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	101.47	127.98	191.44	113.56	144.9	287.31
Short-Term Investments	146.24	88.92	9.95	116.04	74.92	-
Cash & Short-Term Investments	247.71	216.9	201.39	229.6	219.81	287.31
Cash Growth	-12.16%	7.70%	-12.28%	4.45%	-23.49%	29.14%
Other Receivables	1.62	0.7	0.06	0.59	0.13	0.01
Receivables	1.62	0.7	0.06	0.59	0.13	0.01
Prepaid Expenses	13.69	11.12	11.32	10.93	6.94	6.44
Restricted Cash	0.08	0.08	-	-	-	-
Other Current Assets	6.87	3.97	2.56	2.96	2.33	0.18
Total Current Assets	269.97	232.76	215.34	244.07	229.22	293.93
Property, Plant & Equipment	6.56	8.25	12.43	11.43	9.08	3.79
Long-Term Investments	107.26	29.82	-	-	-	-
Other Long-Term Assets	0.72	0.72	0.57	0.57	0.57	0.21
Total Assets	384.51	271.56	228.34	256.07	238.87	297.93
Accounts Payable	4.31	2.5	1.7	0.77	2.39	1.5
Accrued Expenses	21.57	15.49	10.9	12.88	12.71	8.41
Current Portion of Leases	2.3	2.32	2.06	2.36	1.51	1.07
Current Unearned Revenue	8.75	18.99	15.31	14.88	-	-
Other Current Liabilities	1.75	0.75	0.86	0.51	0.54	0.46
Total Current Liabilities	38.68	40.06	30.82	31.39	17.14	11.43
Long-Term Leases	1.26	2.45	4.77	2.72	3.53	0.08
Long-Term Unearned Revenue	9.63	-	33.07	36.86	-	-
Other Long-Term Liabilities	-	0.03	0.11	0.25	0.42	0.34
Total Liabilities	49.57	42.53	68.78	71.22	21.09	11.85
Common Stock	0.01	0.01	0.01	0	0	0
Additional Paid-In Capital	736.28	720	561.43	483.17	414.02	396.35
Retained Earnings	-401.43	-490.83	-401.85	-297.15	-196.08	-110.28
Comprehensive Income & Other	0.1	-0.15	-0.02	-1.18	-0.17	-
Total Common Equity	334.94	229.02	159.57	184.85	217.78	286.08
Shareholders' Equity	334.94	229.02	159.57	184.85	217.78	286.08
Total Liabilities & Equity	384.51	271.56	228.34	256.07	238.87	297.93
Total Debt	3.55	4.77	6.84	5.08	5.04	1.15
Net Cash (Debt)	351.41	241.95	194.56	224.52	214.77	286.16
Net Cash Growth	27.25%	24.36%	-13.34%	4.54%	-24.95%	28.63%
Net Cash Per Share	6.04	4.48	4.42	5.77	5.85	8.55
Filing Date Shares Outstanding	54.8	54.08	46.3	44.15	37.36	36.66
Total Common Shares Outstanding	54.72	54.03	45.92	39.44	36.9	36.58
Working Capital	231.29	192.7	184.52	212.68	212.08	282.51
Book Value Per Share	6.12	4.24	3.47	4.69	5.90	7.82
Tangible Book Value	334.94	229.02	159.57	184.85	217.78	286.08
Tangible Book Value Per Share	6.12	4.24	3.47	4.69	5.90	7.82
Machinery	-	10.31	10.14	8.57	4.93	4.15
Construction In Progress	-	0.12	0.07	0.45	1.61	0.01
Leasehold Improvements	-	2.33	2.29	1.87	0.26	0.21

Updated Aug 12, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q